Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
About IMMUNOGEN INC
Sector
Industry
CEO
Mark Joseph Enyedy
Website
Headquarters
Waltham
Founded
1981
FIGI
BBG000DT8841
ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IMU is 29.00 EUR — it has increased by 0.17% in the past 24 hours. Watch IMMUNOGEN INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange IMMUNOGEN INC stocks are traded under the ticker IMU.
IMU stock is 0.31% volatile and has beta coefficient of 1.27. Track IMMUNOGEN INC stock price on the chart and check out the list of the most volatile stocks — is IMMUNOGEN INC there?
Yes, you can track IMMUNOGEN INC financials in yearly and quarterly reports right on TradingView.
IMMUNOGEN INC is going to release the next earnings report on Jul 29, 2024. Keep track of upcoming events with our Earnings Calendar.
No, IMU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMMUNOGEN INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMMUNOGEN INC technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMMUNOGEN INC stock shows the buy signal. See more of IMMUNOGEN INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.